Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 3 » Issue 2

The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic

Authors Jeffrey R Strawn, Thomas D Geracioti Jr

Published 15 May 2007 Volume 2007:3(2) Pages 237—243

Jeffrey R Strawn1,2,3, Thomas D Geracioti Jr1,2,3

1Department of Psychiatry, University of Cincinnati, College of Medicine, Cincinnati, OH, USA; 2Research and 3Psychiatry Services, Cincinnati Veterans Affairs Medical Center Cincinnati, OH, USA

Abstract: A constellation of pharmacologic treatments for generalized anxiety disorder (GAD) have been developed over the past five decades, although each has a number of potential drawbacks in clinical practice. This review addresses one potentially new pharmacologic treatment for generalized anxiety disorder, the gamma-aminobutyric acid analogue pregabalin. We review the mechanism of action, and pharmacokinetic and pharmacodynamic properties of pregabalin as well as the results of 5 double-blind, placebo-controlled trials of pregabalin in the treatment of generalized anxiety disorder (GAD). Based entirely on data from these industry-sponsored (Pfizer), multi-site clinical trials in patients with GAD, pregabalin appears to be generally well tolerated and has rapid onset of action (approximately 1 week), comparable efficacy to benzodiazepines and lower discontinuation rates compared with other pharmacologic treatments. Thus in GAD, a disorder that is often suboptimally responsive to traditional psychotherapeutic and psychopharmacologic interventions – secondary to poor efficacy, tolerability, and/or side-effects – pregabalin may have a primary role in GAD patients, especially in those with certain psychiatric comorbidities or individuals who are on multi-drug regimens for medical comorbidities.

Keywords: GAD, pregabalin, panic attack, anxiety disorders, antidepressant, anxiolytic

Download Article [PDF] 

Readers of this article also read:

Spirituality in childhood cancer care

Lima NN, do Nascimento VB, de Carvalho SM, Neto ML, Moreira MM, Brasil AQ, Celestino Junior FT, de Oliveira GF, Reis AO

Neuropsychiatric Disease and Treatment 2013, 9:1539-1544

Published Date: 9 October 2013

Remembering and forgetting: directed forgetting effect in obsessive-compulsive disorder

Konishi M, Shishikura K, Nakaaki S, Komatsu S, Mimura M

Neuropsychiatric Disease and Treatment 2011, 7:365-372

Published Date: 15 June 2011

Analysis of sFas IL-6 levels in thyroid-associated ophthalmopathy: Pre- or poststeroid pulse treatment

Kimihito Maeda, Yuichiro Ohara, Masato Hashimoto, Hiroshi Ohguro

Clinical Ophthalmology 2008, 2:609-612

Published Date: 12 September 2008

Impending central retinal vein occlusion associated with cilioretinal artery obstruction

Juliana Mantovani Bottós, Fabio Bom Aggio, Eduardo Dib, Michel Eid Farah

Clinical Ophthalmology 2008, 2:665-668

Published Date: 12 September 2008

Age and disease-related structural changes in the retinal pigment epithelium

Vera L Bonilha

Clinical Ophthalmology 2008, 2:413-424

Published Date: 6 June 2008

Experimental effect of retinoic acids on apoptosis during the development of diabetic retinopathy

Nami Nishikiori, Makoto Osanai, Hideki Chiba, Takashi Kojima, Shuichiro Inatomi, et al

Clinical Ophthalmology 2008, 2:233-235

Published Date: 7 March 2008

Adult neural stem cells: The promise of the future

Philippe Taupin

Neuropsychiatric Disease and Treatment 2007, 3:753-760

Published Date: 15 January 2008

Glatiramer acetate in the treatment of multiple sclerosis

Alex Tselis, Omar Khan, Robert P Lisak

Neuropsychiatric Disease and Treatment 2007, 3:259-267

Published Date: 15 May 2007